H.R. 7837 · 119th Congress · Health

Most Favored Patient Act of 2026

In committee971 words Introduced Mar 5, 2026 · Latest action Mar 5, 2026

How far it has goneStage 2 of 6
  1. IntroducedMar 5, 2026 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.

Who lobbies on it

7 organizations, more than 95% of House bills · 16 filings · Q1 2026–Q3 2026

See which of this bill’s sponsors and cosponsors got money from the lobbying organizations’ PACs → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 3 of 3 quarters
    “…H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues…”

    $26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. America's Health Insurance Plans Inc (ahip) 3 of 3 quarters
    “…H.R. 7837 - Most Favored Patient Act - Rep. Meuser, Daniel - MFN demonstration H.R. 8779 - PBM Act - Rep. Harshbarger, Diana - PBM ownership requirements H.R. 9661 - Expedited Access to Biosimilars Act - Rep. Langworthy, Nicholas - Biosimilar approval requirements H.R. 10227 - INSULIN Act - Rep. DeGette, Diana - Copay…”

    $11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Amgen Inc 3 of 3 quarters
    “…H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act”

    $8.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing

4 more organizations, every filingPROUpgrade

Organizations that named H.R. 7837 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Mar 5, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Mar 5, 2026Introduced in House